Evoke Pharma (NASDAQ:EVOK) Stock Rating Upgraded by Wall Street Zen

by · The Markets Daily

Evoke Pharma (NASDAQ:EVOK – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Evoke Pharma Price Performance

Evoke Pharma stock opened at $5.20 on Friday. The stock has a market cap of $8.11 million, a price-to-earnings ratio of -2.03 and a beta of -0.14. Evoke Pharma has a 1 year low of $1.94 and a 1 year high of $12.32. The firm has a 50-day moving average of $4.89 and a two-hundred day moving average of $3.70.

Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.32). Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.The business had revenue of $3.75 million during the quarter, compared to analysts’ expectations of $3.80 million.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

See Also